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Extracellular vesicles (EVs) are released from cells and enter 
into body fluids thereby providing a toxicological mechanism of 
cell-cell communication. The present study aimed at assessing 
(a) the presence of EVs in mouse body fluids under physiological 
conditions, (b) the effect of exposure of mice to cigarette smoke 
for 8 weeks, and (c) modulation of smoke-related alterations by 
the nonsteroidal anti-inflammatory drug celecoxib, a selective 
cyclooxygenase-2 inhibitor. To this purpose, ICR (CD-1) mice 
were either unexposed or exposed to cigarette smoke, either 
treated or untreated with oral celecoxib. EVs, isolated from 
bronchoalveolar lavage fluid (BALF), blood serum, and urines, 
were analyzed by nanoparticle tracking analysis and flow 
cytometry. EVs baseline concentrations in BALF were remarka-
bly high. Larger EVs were detected in urines. Smoking increased 
EVs concentrations but only in BALF. Celecoxib remarkably 
increased EVs concentrations in the blood serum of both male 
and female smoking mice. The concentration of EVs positive for 
EpCAM, a mediator of cell-cell adhesion in epithelia playing a 
role in tumorigenesis, was much higher in urines than in BALF, 
and celecoxib significantly decreased their concentration. Thus, 
the effects of smoke on EVs concentrations were well detectable 
in the extracellular environment of the respiratory tract, where 
they could behave as delivery carriers to target cells. Celecoxib 
exerted both protective mechanisms in the urinary tract and 
adverse systemic effects of likely hepatotoxic origin in smoke-
exposed mice. Detection of EVs in body fluids may provide an 
early diagnostic tool and an end-point exploitable for preventive 
medicine strategies.
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Introduction
Extracellular vesicles (EVs) are spherical structures 
with a lipid bilayer, which include exosomes, having a 
size of 30-100 nm, microvesicles (MVs), having a size 
of 100-700 nm, and apoptotic bodies, having a size up 
to 5,000 nm, which contain cell organelles and nuclear 
components [1, 2]. The International Society for Extra-
cellular Vesicles proposed a series of criteria, based on 
current best practice, that represent the minimal charac-
terization of EVs [3]. Exosomes are constitutively gen-
erated, stored, and released from the endosomal system, 
whereas MVs are released by outward budding from the 
bi-lipid external membrane of cells [4, 5]. Most, if not 
all, cell types release EVs, which then enter the body 
fluids [6]. Thus, EVs are endogenous delivery carri-
ers that transport molecules to target cells and, travel-
ling from the cells of origin to target cells, they transfer 
their contents after having been internalized [7]. In such 
a way, they provide a mechanism of cell-to-cell com-
munication [8] and of intercellular exchange of cell 
components, such as nucleic acids, cytokines, lipids and 
proteins. Therefore, they act as signals both in cell ho-
meostatic processes and in pathological conditions [9], 
also including inflammation [10] and cancer [11]. EVs 
can be detected in nearly all biological fluids, such as 
blood, urine, saliva, cerebrospinal fluid, bronchoalveo-
lar lavage fluid (BALF), amniotic fluid, seminal plasma, 
and breast milk [2]. Since their content is protected from 
degradation by extracellular proteases and RNases, they 
are highly stable in storage conditions. 
EVs are of particular interest in the study of lung dis-
eases due to the high blood flow and vascular surface 
area of the respiratory tract. Surface proteins play a role 
in EVs pharmacokinetics and in particular in their dis-
tribution to the lung [12]. These biomarkers have been 
investigated in lung diseases, such as pulmonary hyper-
tension  [13], chronic obstructive pulmonary diseases 
(COPD) [14], and lung cancer [15]. Furthermore, it has 
been reported that a variety of environmental and life-
style risk factors, such as air pollutants, smoking, alco-
hol, obesity, nutrition, physical activity, and oxidative 
stress, can modulate EVs trafficking [2].
The assessment of EVs modulation in biological fluids 
is of great importance following exposure to cigarette 
smoke (CS), which is the dominant risk factor for lung 
cancer and, in addition, has been causally associated 
with the induction of other cancers affecting the respi-
ratory tract, urinary tract, digestive system, and hema-
topoietic system [16]. CS is also one of the main risk 
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factors for other chronic degenerative diseases, such as 
BPCO [17]. In vitro studies have shown the relationships 
between exposure to CS and release of EVs, for instance 
by using human macrophages [18], human mononuclear 
cells, depending on Ca2+ mobilization [19], and cultured 
human bronchial epithelial cells [20]. The last effect 
could be prevented by the antioxidant thiols glutathi-
one (GSH) and N-acetyl-L-acetylcysteine (NAC) [20], 
which may contribute to understand the benefits of NAC 
as a chemopreventive agent [21]. In addition, it was 
shown that circulating endothelial MVs can be assumed 
as a measure of early lung destruction and emphysema 
in cigarette smokers [22], and smoking enhanced the 
levels of MVs in blood cells of healthy volunteers [23]. 
Furthermore, the analysis of human BALF showed that 
smoking can alter EVs profiles [24].
The present study had various goals. The first one was 
to evaluate in a preclinical model, under controlled ex-
perimental conditions, the physiological background 
concentration and size of EVs in mouse biological flu-
ids, including BALF, blood serum, and urines, and to 
determine the proportion of EVs of epithelial origin. The 
second goal was to assess how exposure to mainstream 
CS (MCS), which is inhaled by active smokers as an un-
diluted complex mixture, can affect the concentration of 
EVs in these biological fluids. These experiments were 
carried out by using, in part, a subset of mice that had 
been treated in a study evaluating the release of microR-
NAs (miRNAs) in the same biological fluids and, addi-
tionally, in 10 organs of mice exposed to MCS [25, 26]. 
A further goal was to explore whether administration of 
a chemopreventive agent to MCS-exposed mice may be 
able to further modulate the concentration of EVs in bio-
logical fluids. Since chronic inflammation plays a key 
role at different stages of the carcinogenesis process [27] 
and is crucial in CS-related carcinogenesis [28, 29], we 
tested the nonsteroidal anti-inflammatory drug (NSAID) 
celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-
1H-pyrazol-1-yl] benzene-1-sulfonamide, CAS 169590-
42-5). Celecoxib is a selective inhibitor of cyclooxy-
genase-2 (COX-2), the inducible COX isoform having 
a pro-inflammatory function, which is expressed in re-
sponse to certain stimuli such as mitogens, cytokines 
and growth factors [30]). In contrast, COX-1 is the 
housekeeping isoform, the prostaglandins derived from 
COX-1 being involved in the homeostatic maintenance 
of the gastric mucosa. Therefore, selective COX-2 in-
hibitors (coxibs) seem to be safer with regard to gastric 
damage compared to traditional NSAIDs [31]. A ratio-
nale for using celecoxib in these experiments is that, at 
least in synovial fibroblasts, microparticles are able to 
upregulate the production of prostaglandins by inducing 
COX-2 [11].
The results obtained showed that: a) there were baseline 
differences in both size and concentration of total EVs 
and of EVs of epithelial origin in the 3 examined biolog-
ical fluids; b) exposure to MCS significantly increased 
EVs concentrations but only in BALF; and c) treatment 
of MCS-exposed mice with celecoxib further enhanced 
EVs concentrations in the urines and especially in the 
blood serum, which presumably reflects the occurrence 
of toxic effects related to administration of this NSAID.
Materials and methods
Mice and experimental groups
Two-month old Swiss ICR (CD-1) mice of both genders, 
purchased from Harlan Laboratories (San Pietro al Nati-
sone, Udine, Italy), were housed in MakrolonTM cages on 
sawdust bedding and maintained on standard rodent chow 
(Teklad 9607, Harlan Laboratories) and tap water ad libi-
tum. The animal room temperature was 23 ± 2°C, with a 
relative humidity of 55% and a 12 h day-night cycle.
Sixty mice were randomly assigned to 3 experimental 
groups, including mice kept in filtered air for 8 weeks 
(Group 1, sham-exposed mice), mice exposed to MCS 
for 8 weeks (Group 2, MCS-exposed mice), and MCS-
exposed mice treated with celecoxib for the same pe-
riod of time (Group 3). Each group was composed of 10 
males and 10 females.
Housing and treatments of mice were in accordance with 
NIH, European (2010/63 UE Directive), and institution-
al guidelines. The issuance of the NIH Office of Labo-
ratory Animal Welfare (OLAW) with the University of 
Genoa bears the identification number A5899-01 and 
is effective until February 28, 2021. The IACUC pro-
tocol regarding treatment of the same mice for studying 
modulation of miRNAs was approved by the Fox Chase 
Cancer Center Committee on April 13, 2015.
Exposure to MCS and treatment  
with celecoxib
The 40 mice belonging to Groups 2 and 3 were exposed 
whole-body to the MCS generated by Kentucky 2R4F 
reference cigarettes (University of Kentucky, Lexing-
ton, KY), having a declared content of 9.4 mg tar, 0.73 
mg nicotine, and delivering 12 mg CO each. MCS was 
transferred to the exposure chambers by drawing 15 con-
secutive puffs, each of 60 ml and lasting 6 s. Each daily 
session involved 6 consecutive exposures, lasting 10 
min each, with 1-min intervals during which a total air 
change was made in order to avoid excessive accumula-
tion of MCS and toxic effects. The average concentra-
tion of total particulate matter measured in the exposure 
chambers was 784 mg/m3. 
The 20 MCS-exposed mice belonging to Group 3 were 
treated with celecoxib, starting 3 days before the first ex-
posure to MCS. Celecoxib was supplied by the US Na-
tional Cancer Institute (NCI) via MRIGlobal (Kansas 
City, MO). Based on a preliminary subchronic toxicity 
study in Swiss H mice [32], it was decided to incorporate 
celecoxib in the mouse diet at the dose of 1,600 g/Kg diet, 
which corresponded to the 80% of the maximum dose that 
did not produce any body loss or sufferance or alterations 
in the behavior of mice after 6 weeks of treatment.
Collection of body fluids
After 8 weeks, all mice were euthanized. The 2013 AV-
MA guidelines on euthanasia were followed using slow 
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introduction of CO2 for asphyxiation of mice. Death was 
confirmed by absence of respiration and/or heartbeat. 
Cell-free biological fluids were obtained as follows. Im-
mediately after sacrifice, BAL was performed by intu-
bating the trachea and lavaging with 5 ml of phosphate 
buffered saline (PBS) per mouse. The BAL samples 
were centrifuged and the supernatant fluids (BALF) 
were pooled within each experimental group, separate-
ly for males and females. The blood was collected by 
heart puncture and used for preparing serum, which was 
pooled within each experimental group separately for 
males and females. The urine was collected for 8 h and 
pooled from the male mice belonging to each experi-
mental group by using metabolic cages during the day 
preceding euthanasia of mice. The urine was centrifuged 
in order to remove the sediment.
Isolation of EVs from body fluids
Differential ultracentrifugation methods were used to 
isolate EVs from BAL, plasma and urine samples, which 
remain the most widely used primary isolation proce-
dure [33]. In particular, EVs were isolated by ultracen-
trifugation as described previously [1]. Briefly, blood 
serum and BALF samples from male and female mice 
were centrifuged first at 1,000 x g for 5 min to pellet the 
intact cells and then at 2,000 x g for10 min to discard 
the dead cells. The supernatants were further centri-
fuged at 10,000 x g for 30 min in order to remove cell 
debris. EVs were isolated from the final supernatant by 
ultracentrifugation at 100,000 x g for 1 h. The EVs pel-
lets were resuspended in a final volume of PBS corre-
sponding to 1:100 of the original volume. Urine samples 
pooled from male mice were collected and centrifuged 
first at 1,000 x g for 5 min to pellet the intact cells and 
then at 3,000 x g for 10 min at 4°C to remove cell debris. 
The supernatants were further centrifuged at 10,000 x g 
at 4°C for 30 min to remove large membrane fragments 
and other debris. Finally, the supernatants were ultracen-
trifuged at 110,000 x g for 75 min at 4°C [34]. The EVs 
pellets were resuspended in 400 μl PBS filtered 3 times 
through 0.10 μm pore size membranes (EMD Millipore, 
Billerica, MA, USA). 
Nanoparticle Tracking Analysis (NTA)
Concentrations and size of EVs were assessed by na-
noparticle tracking analysis (NTA), a technique that 
measures the Brownian motion of vesicles suspended in 
fluids and displays them in real time through a charge-
coupled device (CCD) camera with high sensitivity. 
Using a NanoSight LM10-HS system (NanoSight Ltd., 
Amesbury, UK), EVs were visualized by laser light scat-
tering. Five 30-s recordings were made for each sample. 
The collected data were analyzed with NTA software, 
which provided high-resolution particle-size distribution 
profiles and concentration measurements of EVs.
EVs characterization 
EVs were characterized by MACSQuant analyzer flow 
cytometer (Miltenyi Biotec, Calderara di Reno, Bologna, 
Italy) according to the customer protocol. 5(6)-carboxy-
fluorescein diacetate N-succinimidyl ester (CFSE) was 
used to discriminate the integrity of the vesicles before 
the specific antibody staining. CFSE is a cell permeant 
non-fluorescent dye. Intracellular esterases in EVs 
cleave the acetate groups which results in the green fluo-
rescent molecule carboxyfluorescein that is membrane 
impermeant. In particular, 60 µl sample aliquots were 
stained with 0.02 μM CFSE at 37°C for 20 min in the 
dark. The CFSE-stained sample was incubated with 6 
μl monoclonal antibody CD326 (EpCAM)-APC (clone: 
caa7-9G8) in the dark for 20 min at 4°C. The double 
staining with CFSE and EPCAM antibody discriminates 
EVs from other contaminants, such as cell membrane 
fragments, and allowed us to quantify the EVs from 
epithelial cells. Thirty μl of double stained sample were 
acquired on the MACSQuant Analyzer. Due to the very 
low amounts of blood serum remaining after Nanosight 
analysis, it was possible to execute the EVs characteriza-
tion analysis only in urine and BALF. 
Statistical analysis
Quantitative data were expressed as the mean ± SD of 
5 replicate recordings. Continuous variables were tested 
for normality and linearity. The comparison between the 
EVs concentration/size curves was made by calculating 
the subtended areas by adding each other histogram col-
umn values recorder for each interval size. The statisti-
cal significance of the differences between groups was 
evaluated by ANOVA followed by Student’s t test for 
unpaired data. P values lower than 0.05 were regarded 
as statistically significant. All statistical analyses were 
performed by using the statistical software Statview 
software (Abacus Concept Inc., Berkeley, CA, USA).
Results
Survival and body weights
All 60 mice survived throughout duration of the experi-
ment (8 weeks). At the beginning of the study, before 
starting the treatments, the body weights (means ± SE) 
were 38.3 ± 0.83 g in the 30 males and 28.8 ± 0.82 g 
in the 30 females. After 8 weeks, the body weights in 
males and females were 42.3 ± 1.09 g and 37.5 ± 1.16 g 
in Group 1 mice (sham-exposed mice), 39.4 ± 0.70 g and 
31.7 ± 1.22 g in Group 2 mice (MCS-exposed mice), and 
34.6 ± 1.55 g and 26.7 ± 1.16 g in Group 3 mice (MCS-
exposed mice treated with celecoxib). The slight body 
weight loss recorded in MCS-exposed mice was statisti-
cally significant in both males (P < 0.05) and females (P 
< 0.01), and it was not further significantly affected by 
administration of dietary celecoxib.
Physiological spread of EVs into body fluids
We first evaluated comparatively the shedding of EVs 
into mouse BALF, blood serum, and urines under base-
line conditions. To this purpose, we used sham-exposed 
male mice, for which all three biological fluids were 
available. As summarized in Figure 1, the EVs differed 
in the body fluids both in size and in concentration. In 
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fact, the EVs curves in blood serum and BALF were uni-
modal, with maximum concentration peaks at a diameter 
of about 170 nm and 230 nm, respectively. In both cases, 
the curves fit a quasi-Gaussian distribution ranging be-
tween 70 and 530 nm, with a queue of larger EVs span-
ning until about 730 nm. Conversely, the EVs curve in 
the urines was multimodal, with two major peaks at 170 
nm and 230 nm, and a minor peak at 430 nm, with a 
more abundant presence of larger EVs. As assessed by 
calculating the areas under the curves, the concentra-
tions of EVs were 41,198.4/µl BALF, 23,436/µl blood 
serum, and 19.462.0/µl urines. The differences between 
blood serum and urines were not statistically significant, 
whereas EVs concentrations in BALF were significantly 
higher than those measured in each one of the other two 
biological fluids (P < 0.05 in both cases).
Concentration of EVs in body fluids  
as related to exposure to MCS  
and treatment with Celecoxib
Figure 2 shows the curves relating the size of EVs to their 
concentrations in the BALF and blood serum of mice of 
both genders and in the urines of male mice as related to 
exposure to MCS and treatment with celecoxib. Expo-
sure to MCS did neither significantly affect the EVs size 
distribution nor their concentrations in blood serum and 
urines, whereas it significantly increased their concen-
trations in BALF, as compared with sham-exposed mice 
(P < 0.001). The oral administration of celecoxib did not 
further affect EVs concentrations in the BALF of MCS-
exposed mice of both genders. In contrast, treatment 
of MCS-exposed mice with celecoxib remarkably and 
significantly (P < 0.001) increased the concentrations of 
EVs in the blood serum of both male and female mice 
as compared to either sham-exposed or MCS-exposed 
mice. In the urine of male MCS-exposed mice, treatment 
with celecoxib caused a slight but significant (P < 0.05) 
increase in the concentrations of EVs in the 150-200 nm 
range as compared with both sham-exposed mice and 
MCS-exposed mice in the absence of the COX-2 inhibi-
tor.
Evaluation of EpCAM-positive EVs
EpCAM was characterized by flow cytometry in the 
BALF of both male and female mice and in the urines of 
male mice, as related to treatment of mice. The resulting 
fluorescence-activated cell sorting (FACS) scatter plots 
are shown in Figure 3, which relates the concentration of 
EpCAM-positive EVs to SSC (Side Scatter) intensity. In 
sham-exposed male mice, the concentration of EpCAM-
positive EVs in urines was much higher than in BALF 
(1,249.2 vs. 55.1 EVs/µl, P < 0.001). 
Following exposure to MCS, the concentration of Ep-
CAM-positive EVs in BALF was significantly increased 
as compared with sham-exposed mice, both males (76.5 
vs. 55.1 EVs/µl, P < 0.05) and females (102.7 vs. 55.4 
EVs/µl, P < 0.001), whereas it was significantly de-
creased in urines (725.3 vs. 1,249.2 EVs/µl, P < 0.05). 
Administration of celecoxib to MCS-exposed mice did 
not affect the concentration of EpCAM-positive EVs in 
the BALF of female mice (115.2 EVs/µl) and slightly 
but significantly increased it in the BALF of male mice 
(108.3 EVs/µl, P < 0.05). Conversely, celecoxib signifi-
cantly decreased the concentration of these EVs in the 
urines of male mice (478.1 EVs/µl, P < 0.05).
Discussion
The results obtained show that, under physiological con-
ditions, the concentrations of EVs in the extracellular 
environment of the 3 examined mouse body fluids is of 
a similar order of magnitude, ranging between almost 
20,000 particles/µl in urines and more than 40,000 parti-
cles/µl in BALF. There were some differences regarding 
the size of EVs, which in BALF and blood serum were 
mainly MVs but also contained some exosomes, where-
as in urines almost all EVs were MVs and included 
larger vesicles having a multimodal distribution. These 
differences correlated with the variable proportion of 
EVs of epithelial origin among total EVs, as assessed by 
evaluating the proportion of EVs positive for EpCAM, 
which was much higher in the case of urines. The low 
proportion of EpCAM-positive EVs in BALF correlates 
with the finding that epithelial cells range from 0.05% 
to 1.5% of the total number of cells recovered in hu-
man BAL samples [35]. It is noteworthy that, besides 
mediating cell-cell adhesion in epithelia [36], EpCAM 
plays a role in tumorigenesis and metastasis of carcino-
mas, being expressed in most neoplastic epithelial cells 
[37]. In fact, normal epithelia express this cell surface 
glycoprotein at a variable but generally lower level than 
carcinomas [38]. 
The data concerning the baseline concentrations of EVs 
in the examined body fluids should be related to the vol-
umes of the same fluids. An adult mouse excretes daily 
Fig. 1. Concentration of EVs according to their size in the BALF 
(dashed line), blood serum (continuous line), and urines (dotted 
line) of sham-exposed male mice.
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around 0.5-1.0 ml urine and has a total blood volume of 
approximately 1.5 ml (https://www.nc3rs.org.uk/mouse-
decision-tree-blood-sampling). More difficult are the 
estimates for BALF. This fluid was obtained by lavag-
ing the lungs of each mouse with 5 ml of physiological 
saline and therefore it is likely that the EVs present in 
terminal airways were considerably diluted in the exam-
ined samples. BAL recovers the pulmonary epithelial 
lining fluid (ELF), which includes the surfactant and 
bronchial-bronchiolar secretions and, in mammals, has 
a relatively constant composition of about 90% lipids 
and 10% proteins. Surfactant lipids, which are produced 
by alveolar type II pneumocytes and to a lesser extent 
by bronchiolar non-ciliated epithelial cells, are synthe-
sized in preformed intracytoplasmic lamellar bodies that 
are secreted into the aqueous subphase of ELF [39]. We 
have no information about the volume of ELF in mice, 
but in humans its volume is pretty high, having been 
reported to be between 37.5 and 75 ml [40]. It should 
be also taken into account that the EVs found in differ-
ent body fluids undergo a different fate. In fact, the EVs 
present in urines get in contact with the mucosae of the 
urinary tract and thereafter are excreted from the body. 
Those present in the bloodstream are either eliminated 
through emunctory organs or transmitted to distant or-
gans. Those found in BALF may trigger cell-to-cell com-
munication mechanisms in bronchoalveolar cells before 
being removed from the lower respiratory spaces via the 
Fig. 2. Size distribution and concentration of EVs in the BALF and blood serum of mice of both genders and in the urines of male mice, 
either sham-exposed (black lines) or exposed to MCS (blue lines) or exposed to MCS and treated with celecoxib (gray lines).
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mucociliary escalator and being either eliminated from 
the body by expectoration or swallowing. Swallowed 
EVs are expected to get in contact with the mucosae of 
the GI tract, thus being either transported to the liver or 
ultimately eliminated with feces. 
Exposure of mice to MCS resulted in a significant in-
crease of EVs in the BALF of both male and female 
mice, whereas the baseline concentrations of EVs 
in blood serum and urines were not affected follow-
ing exposure to MCS. Similar findings were observed 
by evaluating the miRNA profiles in 10 organs and 3 
biological fluids of the same mice used in the present 
study  [25,  26]. In fact, the miRNAs detectable in the 
BALF were mainly of pulmonary origin, whereas the 
skeletal muscle gave a striking contribution to the pres-
ence of MCS-dysregulated miRNAs in the blood serum, 
and the kidney was the main source of miRNAs detect-
able in urines. Among the examined organs, dysregula-
tion of miRNA expression was by far most prevalent in 
the lung, which is consistent with the observed upregula-
tion by MCS of proteins that defend the respiratory tract 
by triggering a variety of protective mechanisms, such 
Fig. 3. Analysis of EpCAM-positive extracellular vesicles in the BALF of mice of both genders and in the urines of male mice, either sham-
exposed or exposed to MCS or exposed to MCS and treated with celecoxib. The x-axis reports the concentration of EpCAM-positive EVs, 
and the y-axis reports the SSC (Side Scatter) intensity, an indicator of granularity. The percentages and concentrations of EpCAM-positive 
EVs within the total EV population are reported inside the red boxes. P1 refers to all EVs, P2 to intact EVs in the 150-500 nm range, and P3 
to EpCAM-positive EVs.
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as antioxidant pathways, detoxification of carcinogens, 
DNA repair, anti-inflammatory pathways, and apopto-
sis. At the same time, however, MCS activates toxic and 
carcinogenic mechanisms, such as modulation of onco-
genes and oncosuppressor genes, cell proliferation, re-
cruitment of undifferentiated stem cells, inflammation, 
inhibition of intercellular communication, angiogenesis, 
invasion, and metastasis  [41]. In addition, exposure of 
mice to MCS in the medium term (7.5-9 months) induc-
es a significant increase in preneoplastic and neoplastic 
lesions and in other histopathological alterations, also 
including malignant tumors in the lung [42].
The distribution patterns of both EVs (present study) 
and miRNAs [25, 26] clearly reflect pharmacokinetic 
mechanisms. Inhaled MCS undergoes a multiorgan dis-
tribution, contains systemic toxicants, and causes can-
cers in about 15 human tissues [16]. Indeed, blood and 
urines can be used to detect some smoking-related al-
terations, such as increased carboxyhemoglobin levels in 
the blood [43] and mutagenicity of urines [44]. However, 
these body fluids do not appear to be suitable substrates 
to detect alterations of other smoking-related biomark-
ers, such as miRNA dysregulation [26] and shedding of 
EVs (present study). This is not exclusive of experimen-
tal data, but also in humans miRNA signatures in plasma 
do not correspond with miRNA signatures in BAL sam-
ples of lung cancer patients [45], and studies in humans 
have suggested that smoking alters lung EVs profiles 
in BALF that are expected to influence the surrounding 
bronchial epithelial cells [24].
Therefore, in spite of the fact that the collection of BALF 
is semi-invasive, the analysis of this fluid appears to be 
more appropriate to detect smoking-related biomarker 
alterations than analysis of blood serum and urine, where 
the alterations of pulmonary origin are confounded by 
contributions from other organs. In fact, BAL has widely 
been used in preclinical and clinical studies because this 
fluid contains both biochemical and cytological indica-
tors of cellular responses to infection, cancer, or inhaled 
drugs or toxicants [46, 47]. 
A further goal of the present study was to evaluate how 
a putative chemopreventive agent can modulate the re-
lease of MCS-related EVs into biological fluids, which 
can be assumed as an indicator either of protective ef-
fects or of adverse effects. Irrespective of gender, the 
oral administration of celecoxib did not further affect 
the increase in EVs concentration in BALF caused by 
exposure of mice to MCS and had poor effects on the 
concentration of EpCAM-positive EVs in this biologi-
cal fluid. This means that this selective COX-2 inhibitor 
failed to modulate the MCS-related release of EVs from 
respiratory tract cells.
On the other hand, celecoxib considerably increased the 
concentrations of EVs in the blood serum of mice of 
both genders exposed to MCS. A similar but less pro-
nounced effect occurred in the urines of MCS-exposed 
male mice, which however was accompanied by a loss 
of EpCAM-positive EVs. Such an effect may correlate 
with the observed protective effects of celecoxib to-
wards induction by MCS of preneoplastic alterations 
in the urinary tract of mice [32]. Moreover, celecoxib 
has been shown to prevent N-butyl-N-(4-hydroxybutyl) 
nitrosamine-induced bladder carcinomas in rats [48]. It 
is noteworthy that urinary EpCAM is overexpressed in 
bladder tumors to such an extent that it could act as a 
biomarker of bladder cancer detection [49]. Thus, our 
results suggest that, even at an early stage, the decrease 
of EpCAM produced by celecoxib in urines may predict 
the protective effects of this drug towards MCS-induced 
neoplastic alterations in the urinary tract.
The increased systemic concentrations of EVs in MCS-
exposed mice treated with celecoxib are likely to be re-
lated to their release from organs other than the lung, 
such as skeletal muscle and liver. In this light, there 
seems to be a relationship between upregulation of cir-
culating EVs by celecoxib and its hepatotoxicity. In fact, 
the dose of celecoxib used in the present study (1,600 
mg/kg diet) did not produce any apparent toxic effect in 
a preliminary 6-week test in smoke-free mice. However, 
in the long-term, this drug became toxic to MCS-ex-
posed mice, as inferred from the decrease in survival and 
body weight gain as well as from some histopathological 
signs of hepatotoxicity in mice treated with celecoxib at 
the same dose [32]. It should be noted that such a dose 
is rather high but is comparable to the pharmacological 
dose in humans. In fact, a dose of 1,000 mg/kg diet of 
celecoxib administered to mice resulted in a plasma con-
centration of 1.6 µg/ml, which approximates the reported 
therapeutic plasma concentration of celecoxib in humans 
[50]. The hepatotoxicity of celecoxib observed in MCS-
exposed mice is consistent with the detection of hepa-
tocellular alterations produced by this drug in rats [51, 
52]. From a mechanistic point of view, it should be taken 
into account that celecoxib is metabolized primarily by 
cytochrome P450 2C9 (CYP2C9)  [53], which at the 
same time is involved in the metabolism of polycyclic 
aromatic hydrocarbons contained in CS [54]. Mediators 
derived from COX-2 have an important hepatoprotective 
function and accordingly the risk of drug-induced liver 
injury may be increased by COX-2 inhibition [55]. In 
fact, an increased clinical vigilance is required during 
the co-administration of celecoxib and other substrates 
or inhibitors of CYP2C9 [50], as it could be the case with 
smoking. Since drug-induced liver damage increases the 
number of circulating EVs [56], it may be assumed that 
the hepatotoxicity caused by celecoxib-induced COX-2 
inhibition in MCS-exposed mice was responsible for the 
observed increase of EVs in blood and urines.
In conclusion, the findings of the present study shed 
light on the role of EVs as biomarkers of exposure to 
MCS, the dominant risk factor for lung cancer, other 
cancers, and other diseases of toxicological relevance. 
It has been postulated that there is immense potential 
for the use of EVs for biomarker detection in clinical 
settings [57]. Our data provide evidence that the ef-
fects of MCS on that end-point are well detectable in 
the extracellular environment of the lower respiratory 
tract, where they could behave as endogenous delivery 
carriers of a variety of molecules to target cells. On the 
other hand, the effects of MCS on EVs release into body 
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fluids were not discernible at a systemic level, presum-
ably due to confounding factors such as the contribution 
from organs other than the lungs. The assay of a puta-
tive chemopreventive agent, the selective COX-2 inhibi-
tor celecoxib, modulated EVs spread at a systemic level 
by suggesting the occurrence of both protective mecha-
nisms in the urinary tract and adverse effects of likely 
hepatotoxic origin in MCS-exposed mice. It should be 
emphasized that these changes were detected after only 
8 weeks of treatment of mice, whereas the development 
of MCS-related tumors and other histopathological al-
terations requires longer periods of time [32]. Therefore, 
the data regarding the spread of EVs in biological fluids 
may be translated to the clinical practice and taken as an 
early diagnostic tool and as an end-point exploitable for 
toxicological studies and preventive medicine strategies.
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